![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-5503
Source: PharmacoEconomics and Outcomes News, Vol.1, Iss.521, 2007-01, pp. : 6-6
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Perphenazine may be best bet in schizophrenia
Inpharma, Vol. 1, Iss. 1574, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Risperidone a better bet for schizophrenia
Inpharma, Vol. 1, Iss. 1260, 2000-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Risperidone a better bet for schizophrenia
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 285, 2000-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Photoselective vaporisation best bet for BPH
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 518, 2006-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Bimatoprost best bet for glaucoma in Europe
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 490, 2005-01 ,pp. :